Treatment of anaemia with erythropoiesis-stimulating agents in patients with chronic kidney disease does not lower mortality and may increase cardiovascular risk: A meta-analysis

Nephron - Clinical Practice

Volumn 121, Issue 3-4, 2013, Pages

  Vinhas, J ^a   Barreto, C ^a   Assuncao J ^a   Parreira, L ^a   Vaz, A ^a  

^a Centro Hospitalar de Setubal   (Portugal)

Author keywords

Anaemia; Chronic kidney disease; Erythropoiesis stimulating agents; Meta analysis

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; FOLLOW UP; HEMATOCRIT; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOSIS; VASCULAR ACCESS; VASCULAR ACCESS THROMBOSIS;

ADULT; ANEMIA; CARDIOVASCULAR DISEASES; COMORBIDITY; ERYTHROPOIETIN; HEMATINICS; HUMANS; INCIDENCE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84869866809     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000345158     Document Type: Article

References (14)

1. Levin A, Thompson CR, Ethier J, et al: Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-134. (Pubitemid 29318806)
2. Abramson JL, Jurkovitz CT, Vaccarino V, et al: Chronic kidney disease, anemia, and incident stroke in a middle-aged, communitybased population: the ARIC Study. Kidney Int 2003; 64: 610-615. (Pubitemid 36871933)
3. Pisoni RL, Bragg-Gresham JL, Young EW, et al: Anemia management and outcomes from countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 94-111. (Pubitemid 38880932)
4. KDOQI, National Kidney Foundation: KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006; 47(suppl 3):S1-S85.
5. Besarab A, Bolton WK, Browne JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590. (Pubitemid 28385655)
6. Singh AK, Szczech L, Tang KL, et al: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2089.
7. Pfeffer MA, Burdmann EA, Chen CY, et al: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
8. Promislow DEL, Tatar M, Pletcher S, Carey JR: Below-threshold mortality: implications for studies in evolution, ecology and demography. J Evol Biol 1999; 12: 314-328. (Pubitemid 29291681)
9. Palmer SC, Navaneethan SD, Craig JC, et al: Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010; 153: 23-33.
10. Schulz KF, Chalmers I, Hayes RJ, Altman DG: Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-412.
11. Higgins JP, Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions, version 5.0.2. The Cochrane Collaboration, 2009. Available from www.cochranehandbook. org.
12. Higgins JPT, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in metaanalysis. BMJ 2003; 327: 557-560.
13. Parfrey PS, Foley RN, Wittreich BH, et al: Double-blind comparison of full and partial anemia correction in incident haemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16: 2180-2189. (Pubitemid 41716451)
14. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, et al: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084. (Pubitemid 44749316)